Samil Pharmaceutical Co.,Ltd (KRX:000520)
South Korea
· Delayed Price · Currency is KRW 11,160
-180 (-1.59%)
At close: Apr 16, 2025, 3:30 PM KST
KRX:000520 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 219,700 | 196,346 | 179,676 | 134,247 | 122,999 | Upgrade
|
| Other Revenue | -0 | - | -0 | - | -0 | Upgrade
|
| Revenue | 219,700 | 196,346 | 179,676 | 134,247 | 122,999 | Upgrade
|
| Revenue Growth (YoY) | 11.89% | 9.28% | 33.84% | 9.14% | 1.56% | Upgrade
|
| Cost of Revenue | 138,785 | 122,275 | 112,191 | 85,259 | 73,967 | Upgrade
|
| Gross Profit | 80,914 | 74,071 | 67,486 | 48,988 | 49,032 | Upgrade
|
| Selling, General & Admin | 68,851 | 61,138 | 57,746 | 43,287 | 37,647 | Upgrade
|
| Research & Development | 6,410 | 5,601 | 2,907 | 2,971 | 3,007 | Upgrade
|
| Other Operating Expenses | 651.37 | 516.12 | 637.98 | 623.15 | 594.91 | Upgrade
|
| Operating Expenses | 80,866 | 67,611 | 63,469 | 48,589 | 42,494 | Upgrade
|
| Operating Income | 48.11 | 6,460 | 4,017 | 399.74 | 6,538 | Upgrade
|
| Interest Expense | -5,057 | -3,545 | -4,263 | -6,202 | -5,505 | Upgrade
|
| Interest & Investment Income | 62.84 | 34.72 | 70.02 | 129.99 | 164.07 | Upgrade
|
| Earnings From Equity Investments | 0.42 | 0.49 | 122.8 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -357.06 | -277.57 | 197.76 | 246.09 | -155.19 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,718 | -2,367 | 580.12 | 299.46 | 183.71 | Upgrade
|
| EBT Excluding Unusual Items | -3,586 | 306.5 | 724.39 | -5,127 | 1,226 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -585 | -7.11 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -27.07 | 1,702 | 340.82 | 365.84 | -27.53 | Upgrade
|
| Pretax Income | -3,613 | 1,424 | 1,058 | -4,761 | 1,198 | Upgrade
|
| Income Tax Expense | 2,016 | -239.76 | 1,086 | 585.31 | -142.5 | Upgrade
|
| Net Income | -5,629 | 1,664 | -28.29 | -5,347 | 1,341 | Upgrade
|
| Net Income to Common | -5,629 | 1,664 | -28.29 | -5,347 | 1,341 | Upgrade
|
| Net Income Growth | - | - | - | - | 70.50% | Upgrade
|
| Shares Outstanding (Basic) | 18 | 14 | 14 | 14 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 18 | 14 | 14 | 14 | 13 | Upgrade
|
| Shares Change (YoY) | 24.32% | 3.75% | 0.82% | 2.85% | 0.13% | Upgrade
|
| EPS (Basic) | -313.00 | 116.16 | -2.03 | -386.63 | 99.70 | Upgrade
|
| EPS (Diluted) | -313.00 | 115.00 | -2.03 | -386.63 | 99.70 | Upgrade
|
| EPS Growth | - | - | - | - | 70.28% | Upgrade
|
| Free Cash Flow | -2,782 | -12,498 | -44,327 | -31,411 | -9,245 | Upgrade
|
| Free Cash Flow Per Share | -154.68 | -864.01 | -3179.28 | -2271.39 | -687.53 | Upgrade
|
| Dividend Per Share | - | - | - | - | 68.182 | Upgrade
|
| Gross Margin | 36.83% | 37.72% | 37.56% | 36.49% | 39.86% | Upgrade
|
| Operating Margin | 0.02% | 3.29% | 2.23% | 0.30% | 5.32% | Upgrade
|
| Profit Margin | -2.56% | 0.85% | -0.02% | -3.98% | 1.09% | Upgrade
|
| Free Cash Flow Margin | -1.27% | -6.37% | -24.67% | -23.40% | -7.52% | Upgrade
|
| EBITDA | 7,311 | 11,828 | 9,006 | 5,112 | 10,738 | Upgrade
|
| EBITDA Margin | 3.33% | 6.02% | 5.01% | 3.81% | 8.73% | Upgrade
|
| D&A For EBITDA | 7,263 | 5,368 | 4,989 | 4,712 | 4,199 | Upgrade
|
| EBIT | 48.11 | 6,460 | 4,017 | 399.74 | 6,538 | Upgrade
|
| EBIT Margin | 0.02% | 3.29% | 2.23% | 0.30% | 5.32% | Upgrade
|
| Effective Tax Rate | - | - | 102.67% | - | - | Upgrade
|
| Advertising Expenses | 8,069 | 8,699 | 11,389 | 7,674 | 6,187 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.